MYCN and neuroblastoma: Guan et al. reported that the compound shows activity both in vitro and in vivo NB models harboring ALK mutations, such as a mouse model of HR-NB driven by Th-ALKF1174L/MYCN, on which crizotinib resulted inactive [205].